They reported the anti-tumor effect studies of 30 MBq 177Lu-LLP2A treatment, alone and combined with immune checkpoint inhibitors (200 μg anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies on days 9, 12, and 15 after tumor cell injection), in B16F10 tumor-bearing mice. Here, CTLA4 is linked to neoplasm.